ImmunOs Therapeutics Secures Significant Funding for Cancer Treatment
ImmunOs Therapeutics AG, an innovative biopharmaceutical company focused on modifying the immune system, has recently announced the successful closing of a Series C financing round that has raised a noteworthy $11 million. This funding will greatly support the company's ongoing clinical trials, which are aimed at developing groundbreaking therapies for cancer.
Key Investors Join Forces
Leading this financing round were well-known existing investors such as Gimv, Pfizer Ventures, Mission BioCapital, and BioMed Partners, who were joined by a new investor, Double Point Ventures. The participation of these esteemed firms underscores a strong belief in ImmunOs Therapeutics' unique capabilities and its bright future in immuno-oncology.
Advancements in Clinical Trials
The funds raised will primarily be allocated to the Phase Ia clinical trial of IOS-1002, the flagship program of ImmunOs, which is being tested both as a standalone treatment and in combination with MSD’s (Merck & Co., Inc.) anti-PD-1 therapy KEYTRUDA. The dual action of IOS-1002 aims to target multiple immune checkpoints, potentially leading to synergies with existing therapies and improved outcomes for patients.
What Makes IOS-1002 Unique?
IOS-1002 stands out as a multifunctional immunotherapy agent specifically designed for advanced solid tumors. Its innovative mechanism focuses on utilizing a naturally occurring human leukocyte antigen (HLA) to target LILRB1, LILRB2, and KIR3DL1. This targeted strategy seeks to enhance both innate and adaptive immune responses, thus modifying the tumor microenvironment and potentially boosting therapeutic effectiveness.
Expert Opinions on Recent Developments
Statements from key executives reveal a hopeful perspective regarding this recent funding. Reinhard Ambros, Executive Chairman of ImmunOs, expressed his excitement about the strong interest from both current and new investors, which highlights the significance of their unique therapeutic strategies. He noted how this funding will propel IOS-1002 forward, strengthening its reputation as a leading HLA-based treatment.
Future Expectations from Key Stakeholders
Campbell Murray, an advisor at Double Point Ventures, commented on the vast potential of ImmunOs’ first-in-class immunotherapy while eagerly anticipating their progress. Michael Baran from Pfizer Ventures also acknowledged ImmunOs’ unique role in offering innovative solutions for inflammatory diseases and immuno-oncology, looking ahead to the forthcoming clinical data reviews.
About ImmunOs Therapeutics AG
Based in Schlieren, Switzerland, ImmunOs Therapeutics AG leverages its HLA-based technology platform to create advanced therapies for cancer and autoimmune diseases. Their lead program, a HLA-fusion protein, has shown promise by effectively binding specific receptors to stimulate both branches of the immune system, with the goal of eliminating tumor cells.
Beyond advancing its therapeutic programs, ImmunOs is also dedicated to expanding its portfolio with various strategies aimed at modulating the immune system, particularly in difficult autoimmune conditions. This holistic approach positions ImmunOs as a comprehensive player in the biopharmaceutical space.
Frequently Asked Questions
What is the primary focus of ImmunOs Therapeutics AG?
ImmunOs Therapeutics is dedicated to developing groundbreaking therapeutics for cancer and autoimmune diseases using its specialized HLA-based technology platform.
What will the recent funding be used for?
The recent $11 million funding is intended to support current clinical trials connected to the IOS-1002 program and help bring it to completion.
Who are the key investors involved in the Series C financing?
Key investors include Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners, and the recently added Double Point Ventures.
What is IOS-1002?
IOS-1002 is an innovative multifunctional immunotherapy developed to address advanced solid tumors by targeting a range of immune checkpoints.
Where is ImmunOs Therapeutics headquartered?
The company is headquartered in Schlieren, Switzerland, where it conducts extensive research and development in the field of immunotherapy.
